Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor VIII is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of von Willebrand Diseases.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
July 08, 2021
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor VIII is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of von Willebrand Diseases.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
August 12, 2019
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor VIII is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
December 18, 2017
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor VIII is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 03, 2016
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A
Details : Xyntha (Factor VIII) is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemophilia A.
Product Name : Xyntha
Product Type : Protein
Upfront Cash : Inapplicable
July 09, 2015
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Male Chinese Subjects With Hemophilia A
Details : Xyntha (Factor VIII) is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Hemophilia A.
Product Name : Xyntha
Product Type : Protein
Upfront Cash : Inapplicable
June 03, 2015
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor VIII is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 06, 2014
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor VIII is a Protein drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 15, 2013
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Human Cell Line-derived Recombinant Factor VIII (Human-cl-rhFVIII) in Previously Untreated Patients
Details : Factor VIII is a Protein drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
October 23, 2012
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Study Phase : Undisclosed
Sponsor : Charta Foundation | Grifols International | CSL Behring | Biotest
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Factor VIII is a Protein drug candidate, which is currently being evaluated in clinical studies for the treatment of Hemophilia A.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 18, 2010
Lead Product(s) : Coagulation Factor VIII
Therapeutic Area : Genetic Disease
Highest Development Status : Undisclosed
Sponsor : Charta Foundation | Grifols International | CSL Behring | Biotest
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
